期刊文献+

肥胖患者全身麻醉诱导期按去脂肪体重与按体重维库溴铵用药的药效学比较 被引量:8

下载PDF
导出
摘要 目的:比较肥胖患者全身麻醉诱导期按去脂肪体重与按体重维库溴铵用药的药效学。方法:选取择期全麻手术患者80例,性别不限,年龄18~64岁,体质指数〉25 kg/m2,随机分为实际体重组(W组)和去脂肪体重组(Q组),每组40例。麻醉诱导:静脉注射丙泊酚1.5 mg/kg和芬太尼5μg/kg,W组和Q组分别静脉注射维库溴铵0.08 mg/kg和0.12 mg/kg(2倍ED95),T1达到最大抑制时气管插管,机械通气,维持Et CO2在正常范围内、BIS值45~55。采用肌松监测仪监测拇内收肌阻滞情况。记录维库溴铵起效时间、T1最大抑制程度,临床作用时间、恢复指数、维库溴铵用量和药理作用时间,计算各指标的变异系数。结果:W组1例患者因手术因素剔除出本研究。两组患者气管插管条件、临床作用时间、恢复指数和药理作用时间的变异系数比较无显著差异。与W组比较,Q组起效时间、T1最大抑制程度和维库溴铵用量的变异系数减小(P〈0.05)。结论:按去脂肪体重给予维库溴铵可减少全麻肥胖患者药效学的个体差异。
出处 《实用医学杂志》 CAS 北大核心 2015年第3期417-419,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献7

  • 1Xiaobo F, Jianjuan K, Yanlin W. Comparsion of the variabili-ty of the onest and recovery from nentomuscular blockeade withcisatracurium versus rocuronium in elderly patients under totalintravenous anesthesia [J]. Braz J Med Biol Res, 2012,45(7):676-680.
  • 2Steinberg D. Influnence of gender on the potency and course ofaction of rocuronium bromide [J]. Rev Esp Anesthesiol Rean-im, 2013,56(10):604-611.
  • 3陈汉文,磨凯,刘中杰,刘辉,梁启波,徐世元.顺苯磺酸阿曲库铵按无脂肪体重与实际体重间断静注给药药效学的对比研究[J].实用医学杂志,2014,30(4):609-612. 被引量:4
  • 4李继庆,段凤梅,王义成,邵贵骞.肥胖患者维库溴铵净体重给药的量效关系[J].临床麻醉学杂志,2009,25(3):265-266. 被引量:9
  • 5磨凯,刘中杰,梁启波,李凤仙,许睿,徐世元.维库溴铵按无脂肪体重给药ED_(95)的测定[J].广东医学,2013,34(4):620-623. 被引量:4
  • 6La colla L,Albertin A,Lacolla G,et al. Predictive performanceof the Minto remifentanil pharmacolinetic parameter set in mor-bidly obese patients enesuin from a new method for calculatinglean body mass [J]. Clin Pharmacokonet, 2010,49 (2) : 131 -139.
  • 7Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics inthe morbidly obese [J]. Br J Anaesth, 2010,105 (suppl 1):16-23.

二级参考文献16

  • 1Leykin Y, Pellis T, Lucca M, et al. The Pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg, 2004,99 : 1086-1089.
  • 2Leykin Y,Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg, 2004,99:1090-1094.
  • 3Gin T, Chan MT, Chan KL, et al. Prolonged neuromuscular block after rocuronium in postpartum patients. Anesth Analg, 2002,94:686-689.
  • 4PUhringer FK, Keller C, Kleinsasser A, et al. Pharmacoki netics of rocuronium bromide in obese female patients. Eur J Anaesthesiol, 1999,16 : 507-510.
  • 5Saitoh Y. Recovery from vecuronium is delayed in patients with hypercholesterolemia, Can J Anaestla, 2006,53 : 556 -561.
  • 6PUHRINGER F K, KELLER C, KLEINSASSER A, et al. Phar- macokinetics of rocuronium bromide in obese patients [ J ]. Eur J Anaesthesiol, 1999, 16(8) : 507 -510.
  • 7LA COLLA L, ALBERTIN A, LA COLLA G, et al. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameterset in morbidly obese patients ensuing from a new method for cal- culating lean body mass[ J. Clin Pharmacokinet, 2010, 49 (2) : 131 - 139.
  • 8PI SUNYER F X. Obesity: criteria and classification [ J ]. Proc Nutr Soc, 2000, 59 (4) : 505 -509.
  • 9VANLINTHOUT E H, BOOIJ L H, VAN EGMOND J, et al. Effect of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pancuronium and at- racurium[J]. Br J Anaesth, 1996, 76(3) :389 -395.
  • 10李继庆,段凤梅,王义成,邵贵骞.肥胖患者维库溴铵净体重给药的量效关系[J].临床麻醉学杂志,2009,25(3):265-266. 被引量:9

共引文献14

同被引文献44

引证文献8

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部